Mesoblast's Ryoncil now listed in all major US drug pricing compendia

Mesoblast (ASX:MSB), a company focused on allogeneic cellular medicines for inflammatory diseases,  announced that pricing information for its product, Ryoncil (remestemcel-L), is now included in all four major drug pricing compendia in the United States.

The listing follows the US Food and Drug Administration's approval and publication of a revised Ryoncil label, which includes updates to Section 16 (How Supplied / Storage and Handling) of the product prescribing information.

The revisions introduce eight new Ryoncil kits, each assigned a unique National Drug Code, allowing treatment centres to order kits tailored to patient-specific weight-based dosages.

The pricing structure ensures uniform pricing regardless of patient weight.

The four drug pricing compendia now listing Ryoncil include: Merative Micromedex RED BOOK, First Databank FDB MedKnowledge drug pricing, Elsevier Gold standard drug database and Wolters Kluwer Medi-Span price Rx.

These compendia serve as official sources for ordering information, including product manufacturing details, kit pricing, and NDCs.

At the time of reporting, Mesoblast's share price was $2.10.